Can-Fite BioPharma Ltd.: Form 20-F for the period ended Dec 31, 2020
Filed with the SEC on Mar 25, 2021 and accepted by EDGAR at Mar 25, 2021, 08:40 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2020-01-01 to 2020-12-31 | $763.0k | us-gaap:Revenues |
| Research and development | 12 months2020-01-01 to 2020-12-31 | $12.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2020-01-01 to 2020-12-31 | −$14.1m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$14.4m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$12.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-01-01 to 2020-12-31 | $26.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-12-31 | $8.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $9.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $9.5m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $1.3m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2020-12-31 | $6.1m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2020-12-31 | 463,769,463 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-21-017630. Last ingested by Listed: Nov 9, 2026, 17:23 ET. Listed shows no prices and gives no investment advice.